Grindeks, the leading pharmaceutical company in the Baltics, is developing new products and at this stage is strengthening its position not only in the European, but also in the world markets. With determination and an innovative approach, Grindek continues to increase the group’s competitiveness, offering new solutions and achieving ambitious goals that turn into real achievements.
Impressive worldwide development – subsidiaries in 29 countries
“Grindeks” has successfully opened subsidiary companies in 29 countries in Europe, North America and Oceania, the employees employed in the companies have already started implementing long-term development plans. “Grindeks” plans to purposefully continue this path of growth, opening subsidiaries in other parts of the world as well. Currently, the company also actively works on innovations and ensures that the pharmaceutical solutions it offers become more and more accessible to people all over the world
Minister of Economy Viktors Valainis: “Grindeks” example shows that Latvian companies are competitive on a global level
Visiting the “Grindeks” production plant at the end of last year, the Minister of Economy Viktors Valainis was convinced that the Latvian pharmaceutical industry has a sustainable future, which is a benefit for the Latvian society and the country as a whole: “exports and innovations are key elements for the development of the Latvian economy and catching up with our neighbors in terms of economic growth. The achievements of “Grindeks” are a good example of the fact that Latvian companies are able to successfully compete at the global level and offer quality products to people all over the world.
During the meeting, the Chairman of the Grindeks Council, Kirovs Lipmans, emphasized the importance of pharmaceutical production in Latvia: “Our country has a strong pharmaceutical industry, which has developed rapidly thanks to the high qualifications of professionals and the investments made. A favorable attitude towards companies is important at the national level, especially towards those, that produce products with high added value.”
Development of modern medicines – 30 new products, more than 100 finished dosage form products are under development
In order to ensure the growing demand for “Grindeks” medicines around the world, the company is actively working on the development of new products, 30 new products were submitted for registration in the last 3 years. Currently, more than 100 finished dosage form products are in the development process to increase patient access to high-quality and effective drugs in medically important therapeutic groups – for the treatment of central nervous system, cardiovascular, diabetes, dermatological and oncological diseases.
Chairman of the board of “Grindeks” Dr. Chem. Juris Hmelnickis: “The opening of new subsidiary companies in 29 countries accurately reflects our strategy. We are strongly committed to offering innovative pharmaceutical solutions worldwide. By expanding our presence, we not only open new representative offices, but also improve people’s health on a global scale.
Health Minister Hossam Abu Meri appreciates the company’s ambitions and dedicated work in strengthening its global export capacity
At the beginning of this year, visiting the “Grindeks” production plant and discussing the issues to be solved in the field of pharmaceuticals, Hosam Abu Meri emphasized: “together with representatives of the industry, we are working on providing the country with critically needed medicines, and local manufacturers and their capacity play an important role in this matter. We have a very strong pharmaceutical industry in Latvia and strong traditions, this is very important at the moment – it is not only a matter of economic and scientific development, it is a matter of security.”
About “Grindeks” concern
“Grindeks” is an international pharmaceutical concern that provides a full product life cycle – research, development, pharmacovigilance, production and sale of original products, patent-free medicines and active pharmaceutical substances. In 2023, the concern exports its products to 103 countries. The main therapeutic groups and directions of “Grindeks” are cardiology, central nervous system, oncology, diabetes, dermatology, cardiology and active pharmaceutical substances. The subsidiary company “Kalceks” specializes in medicines for the hospital segment and ophthalmology.
“Delphi” also follows Instagram or YouTube in the profile – join to find out the most important and interesting things first! The content of the publication or any part of it is a protected copyright object in the sense of the Copyright Law, and its use without the permission of the publisher is prohibited. Read more here
2024-01-21 20:00:03
#Grindeks #significantly #expands #operations #Europe #world
